CRANSWICK PLC financials
CRANSWICK PLC
Country: GB Reporting currency: GBP Latest annual report: 2026-03-28
LEI:
549300LDZLPU51XOSK43 Financial statements
(GBP, as reported — unscaled; 99 line items across 2 annual periods)
| Line item | 2026 | 2025 |
|---|---|---|
| Income statement | ||
| Revenue | £2.98B | £2.72B |
| Depreciation & amortisation | £2.0M | £3.6M |
| Operating profit (EBIT) | £232.8M | £190.6M |
| Finance costs | £17.0M | £9.2M |
| Profit before tax | £215.8M | £181.6M |
| Income tax expense | £57.5M | £47.3M |
| Profit for the year | £158.3M | £134.3M |
| Total comprehensive income | £157.7M | £134.4M |
| Per share | ||
| Basic EPS | £2.96 | £2.50 |
| Diluted EPS | £2.90 | £2.46 |
| Free cash flow / share | £2.05 | £1.44 |
| Cash flow statement | ||
| Cash generated from operations | £322.3M | £257.8M |
| Net cash from operating activities | £275.0M | £216.3M |
| Net cash from investing activities | -£195.2M | -£160.4M |
| Purchase of PP&E (capex) | £163.4M | £137.6M |
| Net cash from financing activities | -£73.2M | -£77.0M |
| Dividends paid | £55.1M | £49.5M |
| Proceeds from borrowings | £33.0M | £18.0M |
| Repayments of borrowings | £1.5M | £0 |
| Lease liability payments | £16.9M | £16.2M |
| Balance sheet | ||
| Total assets | £1.74B | £1.53B |
| Non-current assets | £1.10B | £944.4M |
| Property, plant & equipment | £707.9M | £605.4M |
| Right-of-use assets | £164.6M | £123.7M |
| Intangible assets & goodwill | £219.8M | £210.9M |
| Current assets | £637.5M | £586.8M |
| Inventories | £142.5M | £126.9M |
| Trade & other receivables | £384.6M | £355.0M |
| Cash & equivalents | £12.5M | £5.9M |
| Total equity | £1.09B | £987.9M |
| — attributable to owners | £1.09B | £987.9M |
| Non-current liabilities | £287.2M | £196.1M |
| Lease liabilities (non-current) | £156.5M | £116.3M |
| Current liabilities | £361.2M | £347.2M |
| Lease liabilities (current) | £19.3M | £16.4M |
| Trade & other payables | £340.2M | £328.1M |
| Deferred tax liabilities | £47.0M | £32.0M |
| Derived metrics | ||
| Free cash flow | £111.6M | £78.7M |
| Operating margin | 7.8% | 7.0% |
| Net margin | 5.3% | 4.9% |
| Return on equity | 14.5% | 13.6% |
| Cash conversion ratio | 1.74× | 1.61× |
| Capex coverage | 1.68× | 1.57× |
| Other reported items | ||
| Adjustments For Amortisation Expense | £2.0M | £3.6M |
| Adjustments For Decrease Increase In Biological Assets | £400.0K | -£8.7M |
| Adjustments For Decrease Increase In Inventories | -£10.6M | -£12.8M |
| Adjustments For Decrease Increase In Trade and Other Receivables | -£20.0M | -£26.6M |
| Adjustments For Finance Income Cost | -£17.0M | -£9.2M |
| Adjustments For Gain Loss On Disposals Property Plant and Equipment | -£700.0K | -£900.0K |
| Adjustments For Gains Losses On Change In Fair Value Less Costs To Sell Biological Assets | -£2.2M | -£11.1M |
| Adjustments For Impairment Loss Reversal of Impairment Loss Recognised In Profit Or Loss | £0 | £1.6M |
| Adjustments For Income Tax Expense | £57.5M | £47.3M |
| Adjustments For Increase Decrease In Trade and Other Payables | £4.2M | £3.8M |
| Adjustments For Sharebased Payments | £11.6M | £8.4M |
| Adjustments For Undistributed Profits of Investments Accounted For Using Equity Method | £0 | £200.0K |
| Cash | £12.5M | £5.9M |
| Cash Flows From Losing Control of Subsidiaries Or Other Businesses Classified As Investing Activities | £0 | £200.0K |
| Cash Flows Used In Obtaining Control of Subsidiaries Or Other Businesses Classified As Investing Activities | £30.5M | £25.0M |
| Current Biological Assets | £86.2M | £91.8M |
| Current Financial Assets | £0 | £300.0K |
| Current Financial Liabilities | £500.0K | £300.0K |
| Current Provisions | £1.2M | £2.4M |
| Current Tax Assets | £11.7M | £6.9M |
| Current Tax Relating To Items Charged Or Credited Directly To Equity | -£2.8M | -£1.0M |
| Deferred Tax Relating To Items Charged Or Credited Directly To Equity | £1.3M | -£2.7M |
| Dividends Proposed Or Declared Before Financial Statements Authorised For Issue But Not Recognised As Distribution To Owners Per Share | £0.85 | £0.76 |
| Dividends Recognised As Distributions To Owners Per Share | £0.27 | £0.25 |
| Gains Losses On Cash Flow Hedges Before Tax | -£400.0K | £300.0K |
| Gains Losses On Change In Fair Value Estimates of Biological Assets For Current Period | -£2.2M | -£11.1M |
| Impairment Loss Impairment Gain and Reversal of Impairment Loss Determined In Accordance With IFRS9 | £0 | £1.6M |
| Income Tax Relating To Components of Other Comprehensive Income That Will Be Reclassified To Profit Or Loss | -£200.0K | £100.0K |
| Income Tax Relating To Components of Other Comprehensive Income That Will Not Be Reclassified To Profit Or Loss | £0 | £0 |
| Income Taxes Paid Refund Classified As Operating Activities | £47.3M | £41.5M |
| Increase Decrease In Cash and Cash Equivalents | £6.6M | -£21.1M |
| Increase Decrease Through Sharebased Payment Transactions | £11.6M | £8.4M |
| Interest Paid Classified As Financing Activities | £6.6M | £2.7M |
| Issued Capital | £5.4M | £5.4M |
| Liabilities | £648.4M | £543.3M |
| Net Assets Liabilities | £1.09B | £987.9M |
| Noncurrent Biological Assets | £7.3M | £4.3M |
| Noncurrent Financial Liabilities | £81.2M | £45.6M |
| Noncurrent Investments Other Than Investments Accounted For Using Equity Method | £200.0K | £100.0K |
| Noncurrent Payables | £200.0K | £500.0K |
| Noncurrent Provisions | £2.2M | £1.7M |
| Noncurrent Recognised Liabilities Defined Benefit Plan | £100.0K | £0 |
| Other Comprehensive Income | -£600.0K | £100.0K |
| Other Comprehensive Income Before Tax Gains Losses On Remeasurements of Defined Benefit Plans | -£100.0K | -£200.0K |
| Other Comprehensive Income That Will Be Reclassified To Profit Or Loss Net of Tax | -£500.0K | £300.0K |
| Other Comprehensive Income That Will Not Be Reclassified To Profit Or Loss Net of Tax | -£100.0K | -£200.0K |
| Payments For Debt Issue Costs | £1.8M | £0 |
| Payments To Acquire Or Redeem Entitys Shares | £22.1M | £25.3M |
| Proceeds From Sales of Property Plant and Equipment Classified As Investing Activities | £1.5M | £2.0M |
| Purchase of Interests In Investments Accounted For Using Equity Method | £100.0K | £0 |
| Reclassification Adjustments On Cash Flow Hedges Before Tax | £300.0K | -£100.0K |
| Reserve of Cash Flow Hedges | -£400.0K | £300.0K |
| Reserve of Sharebased Payments | £17.5M | £14.2M |
| Retained Earnings | £971.2M | £870.4M |
| Share of Profit Loss of Associates and Joint Ventures Accounted For Using Equity Method | £0 | £200.0K |
| Share Premium | £135.9M | £133.0M |
Methodology
Every line item above is a fact tagged in CRANSWICK PLC's annual report
filed in the European Single Electronic Format (ESEF) under the IFRS
taxonomy (ifrs-full) — the income statement, balance sheet
and cash-flow statement as the filer reported them. Values are shown
as-is, in the reporting currency (GBP), without
rescaling; the row labels map to the underlying concept name (e.g.
Revenue → ifrs-full:Revenue, Operating profit →
ifrs-full:ProfitLossFromOperatingActivities, Diluted EPS →
ifrs-full:DilutedEarningsLossPerShare), and any concept
without a curated label is shown under “Other reported items” with its
de-camel-cased tag name. Only consolidated, default-member facts are
shown (segment / dimensional breakdowns are excluded).
“Derived metrics” (free cash flow, margins, ROE, …) are computed from those facts by the same model the U.S. financials pages use — not tagged by the filer.
Source: machine-readable OIM xBRL-JSON aggregated by filings.xbrl.org (XBRL International). Entity identity is resolved by LEI via the public-domain GLEIF register. This is reference data, not investment advice.